secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2024-06-12T23:59:59+00:00
Accession:  0001193125-24-159994
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eliem appoints Aoife Brennan as CEO and director, effective upon Tenet merger close
--------------------------------------------------------------------------------

- Aoife Brennan appointed President and CEO, base salary $650K/yr, annual bonus target 55%.
- Equity grant: incentive option for 550K shares and 275K RSUs, vesting over 4 years.
- Stephen Thomas (Tenet CEO) appointed to board, expected to serve as consultant post-merger.
- Andrew Levin to step down as principal executive officer but remain principal financial officer.
- All appointments effective upon closing of Tenet acquisition; meeting on June 26, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000119312524159994/0001193125-24-159994-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000119312524159994/d839370d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-159994

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer